Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $35.37M rose 40.6% year over year, ahead of the +17.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +45.9% a year.

Context

  • Stock-based compensation amounted to 10.2% of revenue in FY2025, down 34.1 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +40.6% holds above the trailing-twelve-month pace of +17.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$35.37M+4.0% QoQ
Last fiscal yearDec 2025
$98.13M+22.8% YoY
LTMJun 2026
$95.64M+17.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.6%——
1 year+22.8%——
3-year CAGR+45.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
98.13M USD
Year-over-year change
+22.8%
4-year CAGR
+38.2%

Stock-Based Compensation vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.1% is the 3rd highest of 7, against a peer median of +9.1%.
  • Stock-based compensation amounts to 7.4% of revenue for MDGL, versus a peer median of 533.0%.
MDGL Competitors
Stock-Based Compensation for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$95.64M USD+17.1%+45.9%7.4%
VKTXViking Therapeutics, Inc.LTM Jun 2026$37.39M USD-5.4%+67.6%—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$33.39M USD-16.1%+143.5%468.9%
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20.28M USD+92.0%+34.5%101.4%
ALTAltimmune, Inc.LTM Mar 2026$15.44M USD+4.6%+25.7%42886.1%
SGMTSagimet Biosciences Inc.LTM Mar 2026$6.82M USD+13.6%+50.8%—
Peer median (excluding MDGL) —+9.1%+59.2%533.0%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Depreciation & Amortization405K467K527K1.1M1.51M
Deferred Income Tax(7.32M)0000
Stock-Based Compensation26.87M31.63M49.74M79.88M98.13M
Change in Working Capital30.65M37.6M(3.28M)(72.35M)(8.5M)
Accounts Receivables000(53.82M)(80.65M)
Inventory000(34.07M)(36.98M)
Accounts Payables20.36M2.45M4.21M15.56M5.28M
Other Working Capital10.29M35.15M(7.49M)(13K)103.86M
Other Non-Cash Items7.32M797K2.41M1.69M7.59M
Operating Cash Flow(183.92M)(224.86M)(324.23M)(455.57M)(189.55M)
Capital Expenditures(209K)(217K)(1.48M)(1.46M)(467K)
Acquisitions (Net)787K(3K)000
Purchases of Investments(394.12M)(143.48M)(834.44M)(1.13B)(1.05B)
Sales of Investments389.27M350.38M333.4M839.19M1.09B
Other Investing Activities(787K)3K019.09M(8.97M)
Investing Cash Flow(5.06M)206.69M(502.52M)(274.39M)32.32M
Debt Repayment050M65M0217.93M
Common Stock Issued170.21M255.38M260.19M397.49M38.06M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.03M8.07M269.93M337.58M0
Financing Cash Flow171.24M313.45M595.12M735.06M255.98M
Effect of Forex Changes000013K
Net Change in Cash(17.74M)295.28M(231.63M)5.1M98.76M
Free Cash Flow(184.13M)(225.07M)(325.71M)(457.03M)(190.02M)

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.